Patents Represented by Attorney, Agent or Law Firm Wendy M. Lee
  • Patent number: 8241630
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: August 14, 2012
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Martin Vanderlaan
  • Patent number: 7981418
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Grant
    Filed: March 1, 2008
    Date of Patent: July 19, 2011
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
  • Patent number: 7976838
    Abstract: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF?-inhibitor.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: July 12, 2011
    Assignee: Genentech, Inc.
    Inventor: Mark C. Benyunes
  • Patent number: 7879325
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: February 1, 2011
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Martin Vanderlaan
  • Patent number: 7862817
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: January 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
  • Patent number: 7741072
    Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
  • Patent number: 7708994
    Abstract: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF?-inhibitor.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: May 4, 2010
    Assignee: Genentech, Inc.
    Inventor: Mark C. Benyunes
  • Patent number: 7618631
    Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and EGFR-targeted drugs.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: November 17, 2009
    Assignee: Genentech, Inc.
    Inventor: Mark Sliwkowski
  • Patent number: 7601335
    Abstract: The present application describes a method for pretreating a biological sample from an autoimmune disease subject in order to avoid interference, especially where the sample is to be subjected to a cell-based biological activity assay, such as a neutralizing antibody assay.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: October 13, 2009
    Assignee: Genentech, Inc.
    Inventors: Krista McCutcheon, An Song
  • Patent number: 7560111
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Grant
    Filed: July 15, 2005
    Date of Patent: July 14, 2009
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Martin Vanderlaan
  • Patent number: 7537931
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: May 26, 2009
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
  • Patent number: 7501122
    Abstract: The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: March 10, 2009
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
  • Patent number: 7498030
    Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and anti-hormonal compounds, such as anti-estrogens.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: March 3, 2009
    Assignee: Genetech, Inc.
    Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
  • Patent number: 7485302
    Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and chemotherapeutic agents.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: February 3, 2009
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
  • Patent number: 7449184
    Abstract: The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: November 11, 2008
    Assignee: Genentech, Inc.
    Inventors: David E. Allison, Rene Bruno, Jian-Feng Lu, Chee M. Ng
  • Patent number: 7416727
    Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: August 26, 2008
    Assignee: Genentech, Inc.
    Inventor: Leonard Presta
  • Patent number: 7371826
    Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: May 13, 2008
    Assignee: Genentech, Inc.
    Inventor: Leonard Presta
  • Patent number: 7371376
    Abstract: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: May 13, 2008
    Assignee: Genentech, Inc.
    Inventor: Brian M. Fendly
  • Patent number: 7371379
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: May 13, 2008
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Patent number: 7364731
    Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326,327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: April 29, 2008
    Assignee: Genentech, Inc.
    Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin